{"filing":{"accession_number":"0001193125-26-257390","cik":"0001658551","ticker":"AMLX","company_name":"Amylyx Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"d128401d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526257390/d128401d8k.htm"},"events":[{"id":6805,"run_id":5962,"accession_number":"0001193125-26-257390","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from Amylyx Pharmaceuticals' Annual Meeting of Stockholders held on June 4, 2026. The filing reports the final vote tallies for three proposals: election of Class II directors (George Mclean Milne Jr., Ph.D. and Paul Fonteyne), ratification of Deloitte \u0026 Touche LLP as independent auditor, and advisory approval of named executive officer compensation. This is a textbook Item 5.07 shareholder vote results disclosure, material to investors as it reflects stockholder decisions on governance and audit matters.","company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4332,"accession_number":"0001193125-26-257390","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Amylyx Pharmaceuticals' Annual Meeting of Stockholders held on June 4, 2026. The filing reports the final vote tallies for three proposals: election of Class II directors (George Mclean Milne Jr., Ph.D. and Paul Fonteyne), ratification of Deloitte \u0026 Touche LLP as independent auditor, and advisory approval of named executive officer compensation. This is a textbook Item 5.07 shareholder vote results disclosure, material to investors as it reflects stockholder decisions on governance and audit matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:23.770729+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4332,"accession_number":"0001193125-26-257390","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Amylyx Pharmaceuticals' Annual Meeting of Stockholders held on June 4, 2026. The filing reports the final vote tallies for three proposals: election of Class II directors (George Mclean Milne Jr., Ph.D. and Paul Fonteyne), ratification of Deloitte \u0026 Touche LLP as independent auditor, and advisory approval of named executive officer compensation. This is a textbook Item 5.07 shareholder vote results disclosure, material to investors as it reflects stockholder decisions on governance and audit matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:23.770729+00:00","company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","filing_date":"2026-06-04"}]}